贝组替凡(Belzutifan) - 药物靶点：HIF-2α_在研适应症：转移性肾细胞癌，副神经节瘤，嗜铬细胞瘤_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Belzutifan (USAN/INN)、MK 6482、MK-6482

+ [5]

靶点

HIF-2α

作用方式

抑制剂

作用机制

HIF-2α抑制剂(内皮PAS结构域包含蛋白-1抑制剂)

治疗领域

肿瘤心血管疾病遗传病与畸形+ [6]

在研适应症

转移性肾细胞癌副神经节瘤嗜铬细胞瘤+ [30]

非在研适应症

终末期肾脏病肝损伤

原研机构

Merck Sharp & Dohme Corp.

在研机构

Merck Sharp & Dohme Corp.Merck Sharp & Dohme LLC

默沙东研发（中国）有限公司

+ [7]

非在研机构-

权益机构

Exelixis, Inc.

Merck & Co., Inc.

Peloton Therapeutics, Inc.

最高研发阶段批准上市

首次获批日期

美国 (2021-08-13),

希佩尔·林道综合征

最高研发阶段(中国)批准上市

特殊审评优先审评 (美国)、突破性疗法 (美国)、加速批准 (美国)、孤儿药 (美国)、优先审评 (中国)、孤儿药 (日本)、孤儿药 (韩国)、附条件批准 (欧盟)、孤儿药 (澳大利亚)

登录后查看时间轴

结构/序列

分子式C17H12F3NO4S

InChIKeyLOMMPXLFBTZENJ-ZACQAIPSSA-N

CAS号1672668-24-4

关联

36

项与贝组替凡相关的临床试验

NCT07593040

/ Not yet recruiting临床2期IIT

A Randomized Phase 2 Trial of Neoadjuvant Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Patients With Localized Renal Cell Carcinoma

This study is designed to evaluate the efficacy of belzutifan in combination with pembrolizumab with or without lenvatinib in the neoadjuvant setting, followed by adjuvant pembrolizumab versus adjuvant pembrolizumab alone, as treatment for participants with intermediate-high and high risk clear cell renal cell carcinoma (ccRCC).

开始日期2026-06-01

申办/合作机构

Vall d'Hebron Institut d'Oncologia

NCT07489495

/ Recruiting临床3期

A Phase 3, Randomized, Double-blind, Study of Belzutifan + Zanzalintinib Versus Belzutifan + Placebo in Participants With Advanced RCC Who Have Progressed on or After Both PD-1/L1 and VEGF-TKI Therapies in Sequence or in Combination (LITESPARK-034)

Researchers are looking for new ways to treat advanced renal cell carcinoma (RCC).
A standard (usual) treatment for certain people with RCC is belzutifan (a study medicine), which is a targeted therapy. Targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. Researchers want to learn if adding another targeted therapy called zanzalintinib (another study medicine) can treat more people with advanced RCC than belzutifan alone.
The goal of this study is to learn if people who receive belzutifan and zanzalintinib live longer overall and without the cancer getting worse compared to people who receive belzutifan and placebo.

开始日期2026-04-09

申办/合作机构

Merck Sharp & Dohme LLC

[+1]

NCT07405164

/ Recruiting临床3期

A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Long-term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study (LITESPARK-043)

Researchers are looking for new ways to treat advanced solid tumors and von Hippel-Lindau (VHL)-related tumors:
* Advanced means the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery
* Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids
* VHL-related tumors are tumors caused by VHL disease. VHL disease is passed down from parents to children and people with VHL disease have a higher chance of getting certain types of cancer
Researchers want to learn about the long-term effects of a trial medicine called belzutifan. Belzutifan, also called MK-6482, is designed to block a protein that helps tumors grow and survive. This is an extension trial, which means only people who were in certain other belzutifan trials (called parent trials) may be able to join. The goal of this trial is to learn how long people live after they start taking belzutifan.

开始日期2026-03-23

申办/合作机构

Merck Sharp & Dohme LLC

100 项与贝组替凡相关的临床结果

登录后查看更多信息

100 项与贝组替凡相关的转化医学

登录后查看更多信息

100 项与贝组替凡相关的专利（医药）

登录后查看更多信息

209

项与贝组替凡相关的文献（医药）

2026-06-01·American journal of ophthalmology case reports

Very rapid response to belzutifan of VHL-related intracranial and retinal hemangioblastomas

Article

作者: Verrico, Antonio ; Hadjistilianou, Doris ; Piatelli, Gianluca ; Borzì, Leonardo ; Mercuri, Claudia ; Milanaccio, Claudia ; Gaggero, Gabriele ; Ramaglia, Antonia ; Molteni, Marta ; Piccolo, Gianluca ; Di Profio, Sonia ; Pagliara, Alessandra ; De Giuseppe, Sara ; Serafino, Massimiliano

Background:

Belzutifan, a hypoxia-inducible factor-2α (HIF-2α) inhibitor approved for von Hippel-Lindau (VHL) disease-related tumors, induces radiological responses in hemangioblastomas, but the timing and extent of early changes are not well defined.

Case presentation:

A 9-year-old girl was admitted with nausea, vomiting, and ataxia. Brain MRI showed a cystic cerebellar mass, which was fully resected; histology and genetic testing confirmed VHL. Follow-up revealed a small stable cerebellar residual. Two years later, she developed multiple retinal hemangioblastomas (RH) with major visual decline and new cerebellar nodules. Argon laser photocoagulation provided no lasting benefit, prompting initiation of belzutifan. The drug was well tolerated over the first six months, with only grade 1 anemia. Psychological assessments documented excellent adaptation, preserved quality of life, stable daily routines, and regular school attendance. MRI demonstrated a marked reduction in two of the three cerebellar nodules as early as day 15 of cycle 1, followed by progressive shrinkage and stabilization by cycle 4. No new RH emerged, and visual acuity improved within eight weeks of treatment and then remained stable.

Conclusions:

This case highlights an unusually rapid radiological response of VHL-associated cerebellar and retinal hemangioblastomas shortly after belzutifan initiation, suggesting that imaging performed soon after treatment onset may detect changes earlier than commonly reported. A slight but measurable improvement in visual acuity was also observed, despite the overall structural stability of the RH. These findings support the potential value of early radiological and functional assessment in selected patients receiving HIF-2α inhibitors.

2026-05-15·JOURNAL OF CLINICAL INVESTIGATION

Genome-wide CRISPR screen identifies a cytokine-enhancer circuit driving HIF-2α activation in renal cancer

Article

作者: Mani, Ram ; Brugarolas, James ; Zhou, Jin ; Bi, Xianju ; Liu, Hongyi ; Zhang, Cheng ; Simon, Jeremy M. ; Nathan, James A. ; Wang, Tao ; Gao, Yunpeng ; Fang, Jun ; Hu, Lianxin ; Adachi, Yayoi ; Liang, Qian ; Liao, Chengheng ; Zhang, Qing

Resistance to HIF-2α inhibitors such as belzutifan underscores the need to better understand how HIF-2α is transcriptionally regulated in clear cell renal cell carcinoma (ccRCC). Here, we uncover a cytokine-driven enhancer mechanism that sustains HIF-2α expression through the JAK1/STAT3 signaling pathway. Using a genome-wide CRISPR screen in von Hippel–Lindau–deficient (VHL-deficient) ccRCC cells, we identified SOCS3 as a key negative regulator of HIF-2α. Mechanistically, loss of SOCS3 activates JAK1/STAT3 signaling, leading to the recruitment of STAT3 to distal enhancers upstream of endothelial PAS domain-containing protein ( EPAS1 ) that physically loop to its promoter to drive HIF-2α transcription. This cytokine-enhancer circuit was recapitulated in samples from patients with ccRCC and functionally validated using CRISPR interference (CRISPRi), which disrupted enhancer-promoter looping and reduced tumor growth in HIF-2α–dependent models. SOCS3 overexpression or pharmacologic inhibition of JAK1/STAT3 markedly suppressed HIF-2α expression and tumor progression both in vitro and in vivo. Unlike prior studies focusing on VHL/HIF occupancy–driven enhancer activation, this work defines a trans -acting cytokine–JAK1/STAT3 pathway that transcriptionally controls EPAS1 . Together, these findings reveal a targetable enhancer mechanism that sustains HIF-2α expression and suggest that combined inhibition of JAK1/STAT3 and HIF-2α may overcome therapeutic resistance in kidney cancer. We discovered that cytokine signaling drives kidney cancer by activating a genetic circuit that boosts HIF-2α expression, offering new targets to overcome treatment resistance.

2026-05-04·JOURNAL OF EXPERIMENTAL MEDICINE

Targeting conserved domains of hypoxia-inducible factors for cancer therapy

Article

作者: Drehmer, Daiana ; Yang, Yongkang ; Wicks, Elizabeth E. ; Chen, Chelsey ; Jackson, Walter ; Lee, Sophia N. ; Salman, Shaima ; Semenza, Gregg L. ; Huang, Tina Y. ; Lyu, Yajing ; Datan, Emmanuel ; Dordai, Dominic ; Hwang, Yousang ; Prabhakar, Nanduri R. ; Peng, Ying-Jie ; Li, Oscar ; Kumar, Anmol ; Cho, Ellen ; MacKerell, Alexander D.

Hypoxia-inducible factors 1 and 2 (HIF-1/2) function as master regulators of cancer progression by regulating angiogenesis, cancer stem cell specification, epithelial–mesenchymal transition, immune evasion, tissue invasion, and metastasis. We utilized computer-aided drug discovery and cell-based reporter assays to identify dual HIF-1/2 inhibitors, which bind directly to highly conserved domains of HIF-1α and HIF-2α, disrupt dimerization with HIF-1β, and trigger proteasomal degradation, thereby inhibiting HIF-1/2 transcriptional activity. These inhibitors and derivative compounds block growth and vascularization of breast, colorectal, head/neck, melanoma, and prostate tumors as monotherapy, and overcome resistance to anti-CTLA-4 or anti-PD-1 immunotherapy, with an aggregate complete response rate of over 50%, through reprogramming of the tumor immune cell microenvironment. Compared with the HIF-2–selective inhibitors belzutifan and PT2385, dual HIF-1/2 inhibitor 1.21S9N showed superior activity against breast and colorectal cancer models, respectively. PT2385 caused breathing abnormalities, whereas 1.21S9N did not. The drugs are orally bioavailable, and no safety concerns were identified even after extended or supratherapeutic dosing.

482

项与贝组替凡相关的新闻（医药）

2026-06-12

·Firstwordpharma

FDA clears Merck & Co.'s Welireg, Keytruda combo in adjuvant kidney cancer

The FDA has approved a combination of Merck & Co.'s Keytruda (pembrolizumab) with the company's HIF-2α inhibitor Welireg (belzutifan) as an adjuvant treatment for adults with clear cell renal cell carcinoma (ccRCC) at risk of recurrence after surgery. The approval also applied to Keytruda's subcutaneous formulation, Keytruda Qlex (pembrolizumab/berahyaluronidase alfa-pmph).The decision, which follows a priority review, is based on the Phase III LITESPARK-022 trial, which enrolled 1841 patients with prior nephrectomy who were at intermediate-high or high risk of recurrence, or who had resected metastases with no evidence of disease. Patients were randomised to receive Welireg plus Keytruda as adjuvant therapy or Keytruda plus placebo.At a prespecified interim analysis, Welireg plus Keytruda was associated with a 28% benefit on the primary endpoint of disease-free survival (DFS), defined as time to recurrence, metastasis or death, with 186 events and 246 events in the Welireg and comparator arms, respectively. Median DFS wasn't reached in either arm, while overall survival (OS) data weren't mature at the interim analysis.Welireg already has a kidney cancer indication, having been approved in late 2023 for advanced RCC patients previously treated with PD-1/L1 and VEGF-targeted therapies (see – KOL Views Q&A: Welireg's safety will aid Merck & Co.'s upstream ambitions in RCC).Meanwhile, Friday's approval gives Keytruda it's fourth kidney cancer indication following two in the first-line advanced setting with Pfizer's Inlyta (axitinib) or Eisai's Lenvima (lenvatinib), and another in the post-nephrectomy setting based on results from the KEYNOTE-564 trial, where it showed a significant 38% improvement in OS in patients with high-risk disease.However, several experts interviewed by FirstWord for a Therapy Trends report last year indicated they planned to stick with Bristol Myers Squibb's Opdivo (nivolumab) for immuno-oncology combinations in RCC given the uncertainty around treatment sequencing (see – Spotlight On: Opdivo combos hold firm in RCC, despite growing pressure from Keytruda).

临床3期临床结果上市批准优先审批免疫疗法

2026-06-12

·fda

FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma

On June 12, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck & Co., Inc.) for the adjuvant treatment of adults with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.Full prescribing information for Welireg, Keytruda, and Keytruda Qlex will be posted on Drugs@FDA.Efficacy and SafetyEfficacy was evaluated in LITESPARK-022 (NCT05239728), a multicenter, double-blind, randomized trial in 1,841 patients with prior nephrectomy for ccRCC who were at intermediate-high or high risk of recurrence, or who had resected metastases with no evidence of disease. Patients were randomized (1:1) to receive belzutifan in combination with pembrolizumab as adjuvant therapy or placebo in combination with pembrolizumab until disease recurrence or unacceptable toxicity or for up to 54 weeks of belzutifan or 12 months of pembrolizumab.The major efficacy outcome measure was investigator-assessed disease-free survival (DFS), defined as time to recurrence, metastasis, or death. A statistically significant improvement in DFS was demonstrated at a prespecified interim analysis with 186 events in the belzutifan with pembrolizumab arm and 246 events in the placebo with pembrolizumab arm (hazard ratio 0.72 [95% CI: 0.59, 0.87]; p-value 0.0003). Median DFS was not reached in either arm. Overall survival data were not mature at the protocol pre-specified interim analysis.The belzutifan prescribing information includes a boxed warning for embryo-fetal toxicity and warnings and precautions for anemia and hypoxia. The pembrolizumab prescribing information includes warnings and precautions for immune-mediated adverse reactions, infusion-related reactions, complications of allogeneic hematopoietic stem cell transplantation, and embryo-fetal toxicity. Recommended DosageThe recommended belzutifan dose is 120 mg orally once daily in combination with pembrolizumab or pembrolizumab and berahyaluronidase-pmph alfa until disease recurrence or unacceptable toxicity, or for up to 54 weeks. The recommended pembrolizumab dose is 200 mg intravenously every three weeks or 400 mg every six weeks in combination with belzutifan 120 mg orally once daily until disease recurrence, unacceptable toxicity, or for up to 12 months. The recommended pembrolizumab and berahyaluronidase alfa-pmph dose is 395 mg/4,800 units subcutaneously every three weeks or 790 mg/9,600 units every six weeks in combination with belzutifan 120 mg orally once daily until disease recurrence, unacceptable toxicity, or for up to 12 months.This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with the Australian Therapeutic Goods Administration (TGA) and Health Canada. The application reviews are ongoing at the other regulatory agencies.This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment.This application was granted priority review. A description of FDA expedited programs is in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics.Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088.For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov.Follow the Oncology Center of Excellence on X (formerly Twitter) @FDAOncology.

优先审批临床结果上市批准临床研究

2026-06-10

·药至诚

收藏！老挝仿制药企两大巨头：卢修斯与大熊制药的部分产品清单！

在肿瘤、慢病治疗中，原研药价格高昂，不少患者家庭面临 “用药难、用药贵” 的困境。老挝作为仿制药生产重地，凭借规范的生产标准和高性价比，成为很多患者的选择。其中，卢修斯制药与大熊制药是老挝仿制药领域的两大标杆企业，产品覆盖肿瘤、血液、肝病等多个领域。今天就为大家详细梳理这两家药企的核心信息与部分产品清单，内容严谨真实，建议收藏备用。一、老挝卢修斯制药（Lucius Pharmaceutical）药企概况卢修斯制药成立于 2020 年，总部位于老挝首都万象，是一家现代化高新生物制药企业卢修斯制药(老挝)有限公司。厂区占地约 21 万平方米，引进中、美、德等国先进制药设备，通过老挝 GMP 认证，部分标准对标欧美药典卢修斯制药(老挝)有限公司。企业专注仿制药研发生产，产品涵盖抗肿瘤、心血管、血液、糖尿病等 200 多个品类，远销全球 50 多个国家和地区，核心优势是靶向药品类全、性价比高卢修斯制药(老挝)有限公司。部分核心产品清单（按适应症分类）1. 肿瘤靶向药（核心品类）贝组替凡（LuciBelzu）：40mg*90 片，用于希佩尔 - 林道综合征相关肿瘤，抑制肿瘤生长与血管生成Lucius Pharmaceutical。沃拉西尼（LuciVora）：40mg*30 片，针对 IDH1 突变型神经胶质瘤及其他 IDH1 突变癌症Lucius Pharmaceutical。他泽司他（LuciTaze）：200mg*56 粒，用于滤泡性淋巴瘤、上皮样肉瘤Lucius Pharmaceutical。康奈非尼（LuciEncor）：75mg*90 粒，治疗 BRAF V600E/K 突变转移性黑色素瘤Lucius Pharmaceutical。贝美替尼（LuciBinim）：15mg*180 粒，与康奈非尼联合治疗 BRAF 突变黑色素瘤Lucius Pharmaceutical。 2. 血液 / 罕见病药物瑞维美尼（LuciRevu）：25mg/110mg/160mg*30 片，用于复发性 / 难治性急性白血病（KMT2A 基因易位）Lucius Pharmaceutical。 3. 代谢疾病药物替尔泊肽（Lucitirze）：注射液，全球首款 GIP/GLP-1 双靶点药物，用于减重及 2 型糖尿病。卢修斯替尔泊肽二、老挝大熊制药（BigBear Pharma）药企概况大熊制药 2021 年建成投产，总部位于老挝万象，是老挝正规化学制药企业，通过老挝新版 GMP 认证，部分产品符合欧盟 GMP 标准老挝大熊制药。企业定位 “健康之星，呵护人群”，是老挝最大的血液及抗病毒药物生产商，产品覆盖肿瘤、血液、肝病、慢病等领域，以 “品质稳定、品类齐全” 著称，部分产品已出口东盟国家。部分核心产品清单（按适应症分类）1. 肿瘤靶向药（核心品类）卡博替尼（CABODX）：20mg/60mg/80mg，多靶点抑制剂，用于肾癌、肝癌、甲状腺癌等。阿来替尼（AILEDX）：150mg，用于 ALK 阳性非小细胞肺癌，入脑效果好。奥拉帕尼（OLADX）：150mg，PARP 抑制剂，覆盖卵巢癌、胰腺癌、乳腺癌等。恩西地平（ENASIDX）：50mg，用于 IDH2 突变急性髓系白血病。依鲁替尼（ILUDX）：BTK 抑制剂，用于慢性淋巴细胞白血病、套细胞淋巴瘤等。大熊制药依鲁替尼2. 血液疾病药物芦可替尼（RUSODX）：15mg，用于骨髓纤维化、真性红细胞增多症。艾曲波帕（ELTROMDX）：50mg，提升血小板计数，用于免疫性血小板减少症。 3. 肝病 / 慢病药物索达（吉三代，SODADX）：400mg/100mg，丙肝泛基因型药物，治愈率高。来那度胺（LENADX）：10mg/25mg，用于多发性骨髓瘤、骨髓增生异常综合征。三、重要误区与用药提醒1. 常见误区 ❌ 误区 1：老挝仿制药 = 假药✅ 正解：正规老挝仿制药企（如卢修斯、大熊）受老挝药监局监管，通过 GMP 认证，产品与原研药生物等效，但价格仅为原研药的 1/3-1/10卢修斯制药(老挝)有限公司。 ❌ 误区 2：仿制药可随意购买服用✅ 正解：仿制药为处方药，需结合病情、基因检测结果，由专业医生指导使用，不可自行购药、调量。 ❌ 误区 3：所有老挝仿制药都靠谱✅ 正解：老挝仿制药市场鱼龙混杂，仅选择有 GMP 认证、官网可查、有正规批号的企业产品，避免购买无资质 “三无” 药品。2. 用药核心提醒合规渠道：通过正规医疗机构、合规海外药房咨询购买，拒绝个人代购（无售后、易买到假药）。疗效差异：仿制药与原研药疗效基本一致，但存在个体差异，用药期间需定期复查，监测疗效与副作用。禁忌人群：过敏者、孕妇、哺乳期女性及肝肾功能不全者，需提前告知医生，评估用药风险。四、总结与互动卢修斯制药与大熊制药作为老挝仿制药领域的两大巨头，凭借规范生产、高性价比、品类齐全的优势，为肿瘤、慢病患者提供了更可负担的用药选择。本文梳理的仅为部分核心产品，两家药企仍有更多血液、免疫、罕见病等领域药物。需要我把这两家药企的核心产品整理成一页速查清单，并标注关键适应症与常见规格，方便你快速对照吗？药至诚往期推荐吃靶向药，查出肺部「新发病灶」，是不是耐药了？该怎么办？ EGFR-TKI 耐药后二线治疗怎么选？11 项大型 III 期研究给出参考排序！海外仿制药全面科普：老挝、印度、孟加拉现状 + 购药合规指南 + 常用药品清单！

一致性评价上市批准

100 项与贝组替凡相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11954	-	-	DB15463

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
转移性肾细胞癌	日本	MSD KK (Tokyo)	2025-06-24
副神经节瘤	美国	Merck & Co., Inc.	2025-05-14
嗜铬细胞瘤	美国	Merck & Co., Inc.	2025-05-14
晚期肾细胞癌	澳大利亚	Merck Sharp & Dohme (Australia) Pty Ltd.	2022-12-22
血管母细胞瘤	澳大利亚	Merck Sharp & Dohme (Australia) Pty Ltd.	2022-12-22
胰腺神经内分泌肿瘤	澳大利亚	Merck Sharp & Dohme (Australia) Pty Ltd.	2022-12-22
肾细胞癌	加拿大	Merck Canada, Inc.	2022-07-11
希佩尔·林道综合征	美国	Merck Sharp & Dohme Corp.	2021-08-13

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
局部晚期透明细胞肾细胞癌	申请上市	欧盟	Merck & Co., Inc.	2024-12-12
不可切除的肾细胞癌	临床3期	美国	Merck Sharp & Dohme LLC	2025-11-26
不可切除的肾细胞癌	临床3期	阿根廷	Merck Sharp & Dohme LLC	2025-11-26
不可切除的肾细胞癌	临床3期	澳大利亚	Merck Sharp & Dohme LLC	2025-11-26
不可切除的肾细胞癌	临床3期	奥地利	Merck Sharp & Dohme LLC	2025-11-26
不可切除的肾细胞癌	临床3期	比利时	Merck Sharp & Dohme LLC	2025-11-26
不可切除的肾细胞癌	临床3期	巴西	Merck Sharp & Dohme LLC	2025-11-26
不可切除的肾细胞癌	临床3期	克罗地亚	Merck Sharp & Dohme LLC	2025-11-26
不可切除的肾细胞癌	临床3期	捷克	Merck Sharp & Dohme LLC	2025-11-26
不可切除的肾细胞癌	临床3期	丹麦	Merck Sharp & Dohme LLC	2025-11-26

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02861573 (KEYNOTE-365, ASCO2026)	临床1/2期	转移性去势抵抗性前列腺癌 Hypoxia-inducible factor 2α (HIF-2α)	21	Belzutifan 120 mg	遞繭廠網憲襯壓鏇淵積(鹽鹽壓襯製構網觸構夢) = 壓繭製窪積壓鹹鑰遞獵製構顧糧獵築獵遞築襯 (繭網構範衊壓築製餘壓, 10.8 ~ NR) 更多	不佳	2026-05-29
ASCO2026	N/A	希佩尔·林道综合征	9	Belzutifan	築遞範夢獵顧築繭壓窪(構製窪襯獵醖觸鏇簾憲) = 廠憲膚顧顧觸壓顧鬱鬱糧範範願積夢窪選構窪 (製醖選網蓋醖遞鬱積醖, 42.1 ~ 99.6) 更多	积极	2026-05-29
LITESPARK-005 (ASCO2026)	N/A	晚期肾细胞癌 tobacco use \| sex \| BMI ... 更多	2,844	Belzutifan	繭製鏇遞鬱選窪遞顧淵(醖積鏇鬱窪壓齋壓窪選) = 憲蓋製壓構獵壓廠蓋積鹽壓衊築糧鹽鏇膚繭廠 (壓夢蓋鬱壓構願窪簾襯 ) 更多	积极	2026-05-29
NCT07227402 (LITESPARK-033, ASCO2026)	临床3期	肾细胞癌辅助	904	Belzutifan plus zanzalintinib	網廠選構壓鹽憲壓窪壓(艱窪壓顧遞襯廠積繭齋) = 膚積襯餘鹽構艱淵憲範顧淵鑰艱夢襯憲觸窪衊 (夢廠觸網窪壓衊壓壓襯 ) 更多	积极	2026-05-29
				Cabozantinib	網廠選構壓鹽憲壓窪壓(艱窪壓顧遞襯廠積繭齋) = 夢襯齋網糧遞襯築艱廠顧淵鑰艱夢襯憲觸窪衊 (夢廠觸網窪壓衊壓壓襯 )
ASCO2026	N/A	肾细胞癌	150	Belzutifan (Responder)	遞糧淵壓襯鑰選簾衊構(鏇遞鬱餘願衊窪積遞鏇) = 淵齋積壓艱餘淵膚鏇艱壓鏇構醖衊範淵簾餘窪 (壓簾艱憲鹹廠壓窪觸窪 ) 更多	积极	2026-05-29
				Belzutifan	遞糧淵壓襯鑰選簾衊構(鏇遞鬱餘願衊窪積遞鏇) = 鑰餘願鹽窪範鬱鹹網範壓鏇構醖衊範淵簾餘窪 (壓簾艱憲鹹廠壓窪觸窪 ) 更多
ASCO2026	N/A	肾细胞癌一线	190	Cabozantinib	壓選齋鬱鹽艱廠鹽壓製(糧製夢觸憲選顧蓋鏇築) = 簾齋簾鹽鬱積夢廠齋衊齋壓積膚憲網淵艱憲淵 (廠衊鬱齋糧鏇醖簾範蓋 ) 更多	积极	2026-05-29
				Belzutifan	壓選齋鬱鹽艱廠鹽壓製(糧製夢觸憲選顧蓋鏇築) = 夢遞觸觸淵夢顧壓觸積齋壓積膚憲網淵艱憲淵 (廠衊鬱齋糧鏇醖簾範蓋 ) 更多
AACR2026	N/A	希佩尔·林道综合征	14	Belzutifan	膚選鑰選鹽獵蓋鏇齋繭(選範積獵壓選淵鏇淵遞) = The most common AEs were anemia (35%), dizziness (21%), and headache (21%). 膚鹹鑰醖鹽鏇網製鏇廠 (顧淵餘壓繭網製鑰選艱 ) 更多	积极	2026-04-21
NCT04586231 (LITESPARK-011, ASCO_GU2026) 人工标引	临床3期	晚期肾细胞癌	747	Belzutifan 120 mg + Lenvatinib 20 mg (IA1)	鏇獵襯繭遞獵鏇齋蓋糧(醖選壓夢簾餘鹽鏇構顧) = 鹽衊築蓋廠構襯觸繭鏇淵顧齋構夢夢艱繭製餘 (鑰夢顧蓋網衊範鏇願鹹, 11.1–16.6) 更多	积极	2026-02-26
				Cabozantinib 60 mg (IA1)	鏇獵襯繭遞獵鏇齋蓋糧(醖選壓夢簾餘鹽鏇構顧) = 鏇鏇蓋蓋鹽鹹衊窪糧鹽淵顧齋構夢夢艱繭製餘 (鑰夢顧蓋網衊範鏇願鹹, 9.2–11.1) 更多
NCT05239728 (LITESPARK-022, ASCO_GU2026) 人工标引	临床3期	肾细胞癌辅助	1,841	Pembrolizumab + belzutifan	觸餘鏇網夢遞鑰簾網鹹(網餘築艱廠窪蓋蓋簾鑰): HR = 0.72 (95% CI, 0.59 ~ 0.87), P-Value = 0.0003 更多	积极	2026-02-26
				Pembrolizumab + placebo
ASCO_GU2026	N/A	肾细胞癌	240	Belzutifan responders	築憲願繭衊餘顧鏇選願(膚鹹願鏇蓋獵構艱襯窪) = 簾網憲衊積蓋齋鬱蓋構齋壓醖範糧獵鹹鬱鏇壓 (糧構獵網廠膚鹽願艱顧 ) 更多	积极	2026-02-26
				Belzutifan non-responders	築憲願繭衊餘顧鏇選願(膚鹹願鏇蓋獵構艱襯窪) = 鏇鏇廠夢壓夢醖選襯遞齋壓醖範糧獵鹹鬱鏇壓 (糧構獵網廠膚鹽願艱顧 ) 更多